Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women’s Health Initiative Study

Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women’s Health Initiative Study

Pancreatic cancer is the fourth leading cause of cancer death. Soluble receptor for glycation end products (sRAGE), which is modulated by anti-hypertensive (HT) medications, has been inversely associated with pancreatic cancer. However, the association between commonly used anti-HT medications and r...

Full description

Bibliographic Details
Main Authors: Zhensheng Wang, Donna L. White, Ron Hoogeveen, Liang Chen, Eric A. Whitsel, Peter A. Richardson, Salim S. Virani, Jose M. Garcia, Hashem B. El-Serag, Li Jiao
Format: Article
Language:English
Published: MDPI AG 2018-08-01
Series:Journal of Clinical Medicine
Subjects:
pancreatic neoplasm
pharmacoepidemiology
hypertension
calcium channel blocker
inflammation
risk factor
sRAGE
Online Access:http://www.mdpi.com/2077-0383/7/8/197

Internet

http://www.mdpi.com/2077-0383/7/8/197

Similar Items